Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia Clinical Trial

Official title:

A Phase II Study Evaluating Venetoclax and Pirtobrutinib in Previously Treated Waldenström Macroglobulinemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05734495
• Other study ID #: 22-611
• Status: Recruiting
• Phase: Phase 2
• Start date: May 2, 2023
• Est. completion date: January 25, 2033

Study information

• Verified date: April 2024
• Source: Dana-Farber Cancer Institute
• Contact: Jorge Castillo, MD
• Phone: 617-632-6045
• Email: jorgej_castillo[@]dfci.harvard.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The names of the study drugs involved in this study are: - Pirtobrutinib (a Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor) - Venetoclax (a BCL2 inhibitor)

Description:

This is a single-arm, open-label, Phase II study to evaluate the safety and efficacy of venetoclax combined with pirtobrutinib (VEN-P) in participants with symptomatic Waldenström Macroglobulinemia (WM) with previously treated disease. Pirtobrutinib blocks a type of protein called Bruton Tyrosine Kinase (BTK) that helps cells live and grow. Venetoclax blocks BCL-2, a protein essential for WM cells' survival. The U.S. Food and Drug Administration (FDA) has not approved pirtobrutinib for Waldenström Macroglobulinemia (WM), but it has been approved for other uses. The FDA has not approved venetoclax for Waldenström Macroglobulinemia (WM), but it has been approved for other uses. The FDA has not approved the combination of pirtobrutinib and venetoclax as a treatment for any disease. Study procedures include screening for eligibility, treatment visits, CT scans, blood tests, and bone marrow aspirates and biopsies. Participants will receive study treatment for up to 2 years and will be followed for up to 4 years or until they start a new therapy. It is expected that about 42 people will take part in this research study. Eli Lilly supports this research study by providing study drug pirtobrutinib and funding.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 42
• Est. completion date: January 25, 2033
• Est. primary completion date: January 25, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Participants must meet the following criteria on screening examination to be eligible to participate. Screening evaluations including consent, physical exam, and laboratory assessments will be done within 30 days prior to Cycle 1 Day 1. Bone marrow biopsy & aspirate, and CT C/A/P will be done within 90 days prior to Cycle 1 Day 1.

• Clinicopathological diagnosis of Waldenström Macroglobulinemia, including MYD88 Wild-Type.
• At least 1 prior line of treatment.
• Prior covalent BTK inhibitor is allowed even if prior progression documented on this agent.
• Prior venetoclax is allowed unless participant had documented progression while on this agent.
• Symptomatic disease meeting criteria for treatment using consensus panel criteria from the Second International Workshop on WM. At least one of the following: --Constitutional Symptoms
• Recurrent fever
• Night sweats
• Fatigue
• Weight loss
• Progressive or symptomatic lymphadenopathy or splenomegaly
• Hemoglobin = 10 g/dL
• Platelet count = 100 k/uL
• Hyperviscosity syndrome
• Symptomatic peripheral neuropathy
• Systemic amyloidosis
• Renal Insufficiency
• Symptomatic cryoglobulinemia
• Age 18 years or older
• Measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum serum IgM level of > 2 times the upper limit normal.
• ECOG performance status =2 (Karnofsky =60%, see Appendix A)
• Women of childbearing potential: Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or have or will have complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) while participating in the study; and 2) for at least 6 months after discontinuation from the study. FCBP must be referred to a qualified provider of contraceptive methods if needed.
• Men must agree to use a latex condom during sexual contact with a female of childbearing potential (FCBP) even if they have had a successful vasectomy 1) while participating in the study; and 2) for at least 6 months after discontinuation from the study.
• Participants must have normal organ and marrow function as defined below:
• Absolute neutrophil count =750/ uL the patient may enroll below this threshold if there is documented bone marrow involvement considered to impair hematopoiesis
• Platelets =50,000/ uL not requiring transfusion support; the patient may enroll below this threshold if there is documented bone marrow involvement considered to impair hematopoiesis
• Hemoglobin = 8 g/dL not requiring transfusion support or growth factors; the patient may enroll below this threshold if there is documented bone marrow involvement considered to impair hematopoiesis or hemolysis
• Total bilirubin = 1.5 X ULN, or =3 x ULN with documented liver involvement, hemolysis, or Gilbert's Disease
• AST(SGOT)/ALT(SGPT) =3 × institutional upper limit of normal, or =5 X ULN with documented liver involvement
• Creatinine clearance = 30 ml/min using Cockcroft/Gault formula
• Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
• Able to adhere to the study visit schedule and other protocol requirements.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Prior exposure to non-covalent BTK inhibitors
• Participants who experienced a major bleeding event or grade > 3 arrhythmia on prior treatment with a BTK inhibitor. NOTE: Major bleeding is defined as bleeding having one or more of the following features: potentially life-threatening bleeding with signs or symptoms of hemodynamic compromise; bleeding associated with a decrease in the hemoglobin level of at least 2g per deciliter; or bleeding in a critical area or organ (e.g. retroperitoneal, intraarticular, pericardial, epidural, or intracranial bleeding or intramuscular bleeding with compartment syndrome).
• Participants who are receiving any other investigational agents.
• Female participants who are pregnant, breastfeeding, or planning to become pregnant or breastfeed while enrolled in this study or within 6 months of last dose of study drug.
• Participants with known CNS lymphoma.
• Participants with known history of Human Immunodeficiency Virus (HIV) and known active cytomegalovirus (CMV) infection.
• Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection based on

criteria below:

• Hepatitis B virus (HBV): Patients with positive hepatitis B surface antigen (HBsAg) are excluded. Patients with positive hepatitis B core antibody (antiHBc) and negative HBsAg require hepatitis B polymerase chain reaction (PCR) evaluation before enrollment. Patients who are hepatitis B PCR positive will be excluded.
• Hepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before enrollment. Patients who are hepatitis C RNA positive will be excluded.
• Concurrent administration of warfarin.
• Concurrent administration of moderate or strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers and/or strong p-glycoprotein (P-gp) inhibitors
• Concurrent systemic immunosuppressant therapy. System steroids at doses <20mg prednisone per day are permitted.
• Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.
• Active uncontrolled systemic bacterial, viral, fungal or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which in the opinion of the Investigator and the Sponsor makes it undesirable for the patient to participate in the trial. Screening for chronic conditions is not required.
• Major surgery within 4 weeks of first dose of study drug.
• Malabsorption syndrome or other condition that precludes enteral route of administration.
• Participants with known history of alcohol or drug abuse.
• Participants with inability to swallow pills and inability to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of the study participation
• Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP]) where new therapy introduced or concomitant therapy escalated within the 4 weeks prior to study enrollment is required to maintain adequate blood counts.
• Prolongation of the QT interval corrected for heart rate (QTcF) > 470 msec on at least 2/3 consecutive electrocardiograms (ECGs), and mean QTcF > 470 msec on all 3 ECGs, during Screening. QTcF is calculated using Fridericia's Formula (QTcF): QTcF=QT/(RR0.33).
• Correction of suspected drug-induced QTcF prolongation can be attempted at the Investigator's discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation.
• Correction for underlying bundle branch block (BBB) allowed. Note: Patients with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker
• Significant cardiovascular disease defined as:
• Unstable angina, or
• History of myocardial infarction within 6 months prior to planned start of pirtobrutinib, or
• Previously documented left ventricular ejection fraction (LVEF) by any method of = 45% in the 12 months prior to planned start of pirtobrutinib; assessment of LVEF via echocardiogram or multigated acquisition (MUGA) scan during Screening should be performed in selected patients as medically indicated, or
• Any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or
• Uncontrolled or symptomatic arrhythmias
• Prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, EKG finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the patient; alter the absorption, distribution, metabolism or excretion of the study drug; or impair the assessment of study results
• Participants with a known hypersensitivity to any of the excipients of pirtobrutinib or venetoclax
• Participants with a history of non-compliance to medical regimens.

Related Conditions & MeSH terms

• Waldenstrom Macroglobulinemia

Intervention

Drug:
• Pirtobrutinib
Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor, tablet taken orally.
• Venetoclax
Small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor, tablet taken orally.

Locations

Country	Name	City	State
United States	Beth Israel Deaconness Medical	Boston	Massachusetts
United States	Dana Farber Cancer Institute	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute	Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Very Good Partial Response (VGPR) or Better Response Rate	VGPR or better response rate is defined as proportion of participants experienced VGPR or complete response (CR) based on modified 6th International Workshop on WM [IWWM] criteria (NCCN 2014).	up to 2 years
Secondary	Best Response	Best response on treatment including complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), stable disease (SD) and progressive disease (PD) per Modified 6th IWWM (NCCN 2014) response criteria.	up to 2 years
Secondary	Median Progression-Free Survival (PFS)	Progression-free survival based on the Kaplan-Meier method is defined as the duration between randomization and documented disease progression (PD) or death, or is censored at time of last disease assessment.	up to 4 years
Secondary	Median Time to Next Treatment (TTNT)	TTNT estimated using the Kaplan Meier method is defined as the duration of time from the first dose of pirtobrutinib until the time of initiation of new therapy, or censored at the date of last contact if no further new therapy initiated.	Up to 6 years
Secondary	Median Duration of Response (DOR)	DOR estimated using the Kaplan Meier method, is defined as the duration of time from the day the criteria are met for response (at least a minor response) to the date that Progressive Disease (PD) or death are objectively documented. Response and PD defined protocol section 11.1.2 - Modified 6th IWWM (NCCN 2014) criteria. If a participant is still responding, then the participant's data will be censored at the last study visit at which a tumor assessment was performed.	up to 4 years
Secondary	Median Overall Survival (OS)	Overall Survival (OS) based on the Kaplan-Meier method is defined as the time from study entry to death or censored at date last known alive.	Up to 6 years
Secondary	Number of Participants Present MYD88 Mutation Status	MYD88 mutation status determined based on allele-specific polymerase-chain-reaction (PCR) assay.	Baseline to 4 years post-treatment
Secondary	Number of Participants Present CXCR4 Mutation Status	CXCR4 mutation status determined based on Sanger sequencing.	Baseline to 4 years post-treatment
Secondary	Number of Participants Present BTK Mutation Status	BTK mutation status determined based on allele-specific polymerase-chain-reaction (PCR) assay.	Baseline to 4 years post-treatment
Secondary	Number of Participants Present BCL2 Mutation Status	BCL2 mutation status determined based on allele-specific polymerase-chain-reaction (PCR) assay.	Baseline to 4 years post-treatment
Secondary	Quality of Life (QOL)	Changes in QOL score will be assessed using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30. The QLQ-C30 summary score is calculated as the mean of the combined 13 QLQ-C30 scale and Item scores, with a higher score indicating a better QOL.	Baseline to up to 6 years from treatment initiation
Secondary	Grade 3-5 Treatment-related Toxicity Rate	All grade 3-5 adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAE v5 as reported on case report forms will be counted. Rate is the proportion of treated participants experiencing at least one treatment-related grade 3-5 AE of any type during the time of observation.	up to 25 months